Treatment with oclacitinib, a Janus kinase inhibitor, down-regulates and up-regulates CD25 and Foxp3 expression, respectively, in peripheral blood T cells of dogs with atopic dermatitis.

BMC Vet Res · 2024 · PMC11515184 · PMID 39462373

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

a strong trendp = 0.06so close (0.05 < p ≤ 0.1)

1 C); moreover, a strong trend ( p = 0.06) toward increasing this parameter was found at the lower concentration of the drug (Fig. 1 C).

also in 1,659 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.